Aadi Bioscience, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$39.6M
Doctors Paid
583
Transactions
2,682
2024 Total
$21.2M
Payment Breakdown by Category
Research$38.8M (97.9%)
Consulting$342,321 (0.9%)
Food & Beverage$51,210 (0.1%)
Travel$29,303 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.8M | 1,512 | 97.9% |
| Honoraria | $366,675 | 141 | 0.9% |
| Consulting Fee | $342,321 | 82 | 0.9% |
| Food and Beverage | $51,210 | 827 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,305 | 19 | 0.1% |
| Travel and Lodging | $29,303 | 66 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $14,000 | 4 | 0.0% |
| Education | $5,024 | 31 | 0.0% |
Payments by Type
Research
$38.8M
1,508 transactions
General
$850,838
1,170 transactions
Ownership
$0
4 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) | $14.9M | 0 | 51 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1 | $7.1M | 0 | 31 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | $6.3M | 0 | 327 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | $3.7M | 2 | 467 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | $2.7M | 1 | 271 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors NETs of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $2.5M | 0 | 4 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $494,611 | 0 | 315 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | $475,934 | 0 | 23 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | $294,203 | 0 | 2 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | $218,068 | 0 | 8 |
| A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa | $58,869 | 0 | 5 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $38,440 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors — Page 5
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Charlene Mantia, M.d, M.D | Medical Oncology | Boston, MA | $1,500 | $0 |
| Michael Lattanzi | Medical Oncology | Austin, TX | $1,500 | $0 |
| Dr. Joyce O'shaughnessy, Md, MD | Medical Oncology | Dallas, TX | $1,350 | $0 |
| Dr. Allen Cohn, Md, MD | Hematology & Oncology | Denver, CO | $1,117 | $0 |
| Ioana Hinshaw, Md, MD | Hematology & Oncology | Denver, CO | $1,000 | $0 |
| Daniel George, M.d, M.D | Urology | Durham, NC | $1,000 | $0 |
| Dr. Brian Vicuna, Md, MD | Medical Oncology | Las Vegas, NV | $1,000 | $0 |
| Dr. Mahesh Seetharam, Md, Facp, MD, FACP | Hematology & Oncology | Phoenix, AZ | $1,000 | $0 |
| Dr. John Renshaw, M.d, M.D | Hematology & Oncology | San Antonio, TX | $1,000 | $0 |
| Fadi Braiteh, M.d, M.D | Internal Medicine | Las Vegas, NV | $1,000 | $0 |
| Makenzi Evangelist, M.d, M.D | Hematology & Oncology | Albany, NY | $1,000 | $0 |
| Dr. Purvi Gada, Mbbs, MBBS | Internal Medicine | Chaska, MN | $1,000 | $0 |
| Dr. Donald Richards, Md, MD | Medical Oncology | Tyler, TX | $1,000 | $0 |
| Petros Grivas, M.d, M.D | Medical Oncology | Seattle, WA | $1,000 | $0 |
| Dr. Habte Yimer, M.d, M.D | Hematology | Tyler, TX | $1,000 | $0 |
| Jamal Joudeh, Md, MD | Internal Medicine | Pensacola, FL | $1,000 | $0 |
| Lara Davis, Md, MD | Internal Medicine | Seattle, WA | $984.53 | $0 |
| Elena Chiorean, M.d, M.D | Hematology & Oncology | Seattle, WA | $900.00 | $0 |
| Sudha Yalamanchili, Aprn, APRN | Family | Houston, TX | $814.97 | $0 |
| Aditya Bardia, Md, MD | Medical Oncology | Santa Monica, CA | $800.00 | $0 |
| Naveen Sharma, Md, MD | Specialist | Ventura, CA | $800.00 | $0 |
| Himisha Beltran, Md, MD | Medical Oncology | Boston, MA | $800.00 | $0 |
| Dr. Gino In, Md, MD | Hematology & Oncology | Los Angeles, CA | $799.02 | $0 |
| Gabriel Mannis, Md, MD | Internal Medicine | Stanford, CA | $750.00 | $0 |
| Dr. Tejas Patil, M.d, M.D | Hematology & Oncology | Aurora, CO | $685.00 | $0 |
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc. has made $39.6M in payments to 583 healthcare providers, recorded across 2,682 transactions in the CMS Open Payments database. In 2024, the company paid $21.2M. The top product by payment volume is FYARRO ($23.1M).
Payments were distributed across 46 medical specialties. The top specialty by payment amount is Medical Oncology ($341,757 to 68 doctors).
Payment categories include: Food & Beverage ($51,210), Consulting ($342,321), Research ($38.8M), Travel & Lodging ($29,303).
Aadi Bioscience, Inc. is associated with 3 products in the CMS Open Payments database.